|
KMID : 1143420220150241674
|
|
Public Health Weekly Report
2022 Volume.15 No. 24 p.1674 ~ p.1688
|
|
|
Safety monitoring of Novavax COVID-19 vaccine from February 14 to May 7, 2022
|
|
Kim Seon-Tae
Heo Ye-Seul
Ko Mi-Jeong
Seo Soon-Yeoung
Lim Do-Sang
Cho En-Hi
Lee Yeon-Kyeng
|
|
|
Abstract
|
|
|
|
In the Republic of Korea (ROK), the Novavax coronavirus disease 2019 (COVID-19) vaccination was rolled out on February 14, 2022, for persons aged ≥18 years. In order to identify potential adverse events for rapid responses, a text message-based survey was conducted among persons who completed Novavax vaccination, in parallel with adverse event reports by doctors, in accordance with the Infectious Disease Control and Prevention Act. This report aimed to analyze the data on adverse events following Novavax vaccination reported to the COVID-19 vaccination management system (CVMS) from February 14 to May 7, 2022, in addition to the text message-based survey asked about health conditions and adverse events following the primary Novavax vaccination series including the first and second doses between February 21 and April 24, 2022. During this period, a total of 666 adverse events following Novavax vaccination were reported in the CVMS; 95.6% of them were non-serious adverse events such as myalgia and headache. The overall reporting rate per 100,000 doses administered was 154.8. According to the text message survey, the most frequently reported adverse events after either dose 1 or dose 2 were pain at the injection site, fatigue or tiredness, and myalgia, and they disappeared gradually 1-2 days after vaccination. In addition, the response rate of adverse events was higher among persons aged 18-64 years than that among persons aged ≥65 years, with more reports after dose 2 than after dose 1, which are consistent with previous findings such as clinical trials. This report aimed to identify the safety profile of the Novavax vaccine, recently introduced in the ROK, by analyzing data on adverse events following Novavax vaccination. To promote safe COVID-19 vaccination programs in the ROK, we will continue to monitor any adverse events following vaccination and share up-to-date information on vaccine safety with relevant committees and experts.
|
|
|
KEYWORD
|
|
|
COVID-19 vaccination, Novavax, Adverse events, Vaccine safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|